Atlas-backed Remix adds $70M series B, building on J&J deal

Remix’s new $70 million series B round brings a crossover investor into the fold, bringing the start-up’s total capitalization to nearly $200 million since its 2019 inception.

The cash extends the runway for Remix Therapeutics Inc. as it advances its preclinical pipeline of small molecules designed to alter how cellular complexes process RNA while circumventing some tissue distribution challenges of RNAi and antisense approaches. The platform includes data science and bioinformatics elements, screening technology and Remix’s own chemical library...